1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The successful demonstration of feasibility and tolerability could open new avenues for managing obesity in patients with advanced lung disease, potentially improving their quality of life and clinical outcomes. If Se…
Reducing injection site pain is a critical factor for improving patient adherence to long-term therapies like Semaglutide, which is often administered weekly for chronic conditions such as Type 2 Diabetes and Obesity.…
This regulatory post-marketing surveillance study is crucial for gathering real-world evidence on oral semaglutide, complementing data from controlled clinical trials. Such data is vital for understanding how the drug…
This Phase 2 trial is crucial as it explores a novel combination therapy that could significantly advance the treatment landscape for obesity and Type 2 Diabetes. If successful, combining LY3841136 with Tirzepatide co…
This study addresses a critical unmet need for patients with psoriatic arthritis who also struggle with obesity, a common comorbidity that complicates disease management and often reduces the effectiveness of existing…
This research underscores a critical challenge in obesity management, suggesting that the benefits of Tirzepatide on weight loss may necessitate continuous or long-term administration to prevent relapse. The rapid wei…
Understanding the effects of GLP-1 agonist discontinuation is crucial for informing patient care and developing strategies to manage potential rebound effects and improve long-term outcomes. Many patients may need to …
Tirzepatide is already a highly effective treatment for Type II Diabetes and obesity, known for its significant glycemic control and weight loss benefits. The key implication of this study is that if Tirzepatide can d…
The review revealed a consistent and significant dysregulation of both orexin and GLP-1 signaling in post-viral syndromes, suggesting their central role in the manifestation of diverse symptoms. Multiple studies indic…
This study provides compelling real-world evidence that low-to-moderate doses of Tirzepatide are highly effective and well-tolerated for weight management in adults with obesity in routine clinical practice. The obser…
This review underscores the critical role of tailored dietary strategies in maximizing the therapeutic benefits of GLP-1 and dual GIP/GLP-1 receptor agonists. It suggests that integrating specific nutritional guidance…
This study provides crucial real-world evidence that Tirzepatide not only induces substantial weight loss but also favorably alters body composition by preserving lean mass and significantly improving muscle function …
This study provides compelling and definitive evidence that Semaglutide offers direct and substantial cardiovascular benefits in individuals with established cardiovascular disease and overweight or obesity, independe…
This landmark study provides compelling evidence that semaglutide offers significant cardiovascular protection beyond its known weight loss benefits, even in individuals without diabetes. The 20% reduction in major ad…
This study represents a paradigm shift in the management of cardiovascular risk in individuals with obesity. It unequivocally demonstrates that a GLP-1 receptor agonist, semaglutide, can directly reduce major cardiova…
This comprehensive review underscores that optimizing nutritional support is absolutely essential for maximizing the therapeutic benefits and minimizing potential risks associated with GLP-1 receptor agonist therapies…
This comprehensive review provides a critical, evidence-based framework for clinicians managing Type 2 Diabetes, moving beyond a glucose-centric approach. It underscores the importance of personalized medicine, where …
These Stage 1 results from the Daybreak trial provide compelling evidence for the efficacy of Setmelanotide as a targeted therapeutic option for patients with early-onset, severe obesity and hyperphagia driven by MC4R…
This comprehensive bibliometric analysis provides a crucial roadmap for understanding the evolving landscape of GLP-1 RA adverse effect research. The findings identify key research hotspots and neglected areas, guidin…
This comprehensive meta-analysis solidifies the role of GLP-1 agonists as highly effective treatments for weight loss and improved body composition in adults with overweight or obesity. The significant reduction in fa…
This comprehensive systematic review solidifies the evidence for GLP-1 RAs as crucial therapeutic agents for cardiovascular protection, extending their benefits far beyond glucose control and weight management. These …
This comprehensive review provides crucial evidence for clinicians to make informed decisions when prescribing pharmacological interventions for weight management in non-diabetic adults. The significant weight loss ob…
This research highlights brain glucose hypometabolism as a crucial, early indicator of Alzheimer's Disease risk. Understanding this sequence could revolutionize early diagnostic strategies, allowing for interventions …
This Mendelian Randomization study provides robust genetic evidence for the causal long-term benefits and safety of GLP-1R agonists and SGLT2 inhibitors extending beyond their current use in high-risk patients. The fi…
This review is crucial for guiding future research and clinical practice in the rapidly evolving landscape of GLP-1 therapies, emphasizing a holistic approach to patient care. Understanding the psychological dimension…
This research strengthens the understanding of metformin's mechanism of action beyond its primary glucose-lowering effects, highlighting its sustained impact on GLP-1, a key hormone for glucose homeostasis and appetit…
This comprehensive real-world data provides crucial insights for clinicians and patients navigating treatment options for Type 2 Diabetes and obesity. The findings underscore Tirzepatide's potential for greater metabo…
While this specific study was terminated without reporting results, the underlying research question remains highly relevant. If completed, positive findings could have highlighted Liraglutide's potential beyond weigh…
If IBI362 demonstrates superior or comparable efficacy with a favorable safety profile against dulaglutide, it could represent a significant advancement in Type 2 Diabetes management. This would provide a new therapeu…
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
The successful completion of this Phase III trial could establish IBI362 as a novel and effective treatment option for MAFLD, a condition with limited approved pharmacotherapies. Given the high prevalence of MAFLD in …
The successful completion of this early-phase trial is a significant step forward for IBI362, a novel therapeutic candidate for Type 2 Diabetes. This foundational data on its human safety, tolerability, and drug profi…
The successful completion of enrollment for this Phase III trial is a significant milestone in the development of new therapies for NASH and obesity. Given the limited treatment options for NASH, a condition affecting…
This Phase 1 study is crucial for the continued development of survodutide, as it provides foundational data on how the drug behaves in a specific ethnic population. Understanding the pharmacokinetics and safety profi…
If the results demonstrate significant and sustained weight loss, survodutide could represent a major advancement in the treatment of obesity and overweight, offering a new, potent therapeutic option. This is particul…
While this specific study did not yield data, the initial intent highlights a critical area of need: understanding how combination therapies like IDegLira perform in real-world settings for patients whose Type 2 Diabe…
Liraglutide is already a cornerstone in managing Type 2 Diabetes and has demonstrated significant cardiovascular benefits, including a 13% reduction in major adverse cardiovascular events in previous trials. This stud…
Understanding the interaction between Liraglutide and clock genes could provide novel insights into the pathogenesis of Type 2 Diabetes and the broader metabolic effects of GLP-1 receptor agonists. This research is cr…
The abstract outlines the study's primary objective to determine the effectiveness and safety of adding GLP-1 agonist therapy to basal insulin. The investigators hypothesized that this combination would lead to statis…
This Phase 3 trial is crucial for optimizing Type 2 Diabetes management by evaluating a potentially simpler, yet effective, treatment option. If IDegLira demonstrates comparable efficacy and a favorable safety profile…
This study provides strong evidence supporting the enhanced efficacy of combining a basal insulin (insulin degludec) with a GLP-1 receptor agonist (liraglutide, a class of drugs that mimic a natural hormone to lower b…